Antineoplastic drugs as a potential risk factor in occupational settings: Mechanisms of action at the cell level, genotoxic effects, and their detection using different biomarkers;Antineoplastični Lijekovi Kao Čimbenik Rizika u Radnom Okolišu: Mehanizmi Djelovanja na Razini Stanice i Pregled Metoda za Otkrivanje Njihovih Genotoksičnih Učinaka

Arhiv za Higijenu Rada i Toksikologiju

Volumn 61, Issue 1, 2010, Pages 121-146

  Kopjar, Nevenka ^a   Želježić, Davor ^a   Kašuba, Vilena ^a   Rozgaj, Ružica ^a  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

Chromosome aberrations; Comet assay; DNA; Izmjene sestrinskih kromatida; Komet test; Kromosomske aberacije; Micronuclei; Mikronukleus test; Sister chromatid exchanges

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

BIOLOGICAL MONITORING; DRUG DETERMINATION; DRUG EXPOSURE; DRUG MECHANISM; GENOME ANALYSIS; GENOTOXICITY; HUMAN; MICRONUCLEUS TEST; OCCUPATIONAL EXPOSURE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; CHROMOSOME ABERRATION; COMET ASSAY; DNA DAMAGE; DRUG EFFECT; HEALTH CARE PERSONNEL; SISTER CHROMATID EXCHANGE;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; COMET ASSAY; DNA DAMAGE; HEALTH PERSONNEL; HUMANS; MICRONUCLEUS TESTS; OCCUPATIONAL EXPOSURE; SISTER CHROMATID EXCHANGE;

EID: 77950253491     PISSN: 00041254     EISSN: None     Source Type: Journal    
DOI: 10.2478/10004-1254-61-2010-2025     Document Type: Review

References (212)

1. National Institute for Occupational Safety and Health (NIOSH). NIOSH Alert. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. Publication Number 2004-2165 Cincinatti (OH): NIOSH Publication Dissemination; 2004.
2. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2010 [pristup 17. siječnja 2010.]. Dostupno na http://www.whocc. no/filearchive/publications/2010guidelines.pdf.
3. Vrhovac B, urednik. Farmakoterapijski priručnik. 4. izd. Zagreb: Medicinska naklada; 2003.
4. International Agency for Research on Cancer (IARC). Complete List of Agents evaluated and their classification [pristup 17. siječnja 2010.]. Dostupno na http://monographs. iarc.fr/ENG/Classification/index.php.
5. International Agency for Research on Cancer (IARC). Agents reviewed by the IARC Monographs Volume1-100A (by CAS numbers) [pristup 17. siječnja 2010.]. Dostupno na http:// monographs.iarc.fr/ENG/Classification/ ListagentsCASnos. pdf.
6. International Agency for Research on Cancer (IARC). Summaries and Evaluations: Melphalan, Medphalan and Merphalan [pristup 17. siječnja 2010.]. Dostupno na http:// www.inchem.org/documents/iarc/vol09/melphalan.html.
7. Falck K, Grohn P, Sorsa M. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979;1:1250-1251
8. Sanderson BJ, Shield AJ. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res 1996;355:41-57.
9. Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticencer drugs. Mutat Res 1996;355:59-70.
10. Jacobson MA, Stack HF, Waters MD. Genetic activity profiles of anticancer drugs. Mutat Res 1996;355:171-208.
11. Singh B, Gupta RS. Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and sister chromatid exchanges in chinese hamster ovary cells. Cancer Res 1983;43:577-584
12. Page C, Curtis M, Sutter M, Walker M, Hoffman B, urednici. Integrated Pharmacology. 2. izd. Edinburgh: Mosby International Ltd.; 2002.
13. Rang HP, Dale MM, Riffer JM, Moore PK, urednici. Pharmacology. 5. izd. Edinburgh: Churchill Livingstone; 2003.
14. Henke Yarbro C, Hansen Frogge M, Goodman M, urednici. Cancer Nursing: Principles and Practice. 6. izd. Sudbury: Jones and Bartlett Publishers Inc.; 2005.
15. Drablos F, Feyzi E, Aas PA, Vaagbo CB, Kavli B, Bratlie MS, Pena-Diaz J, Otterlei M, Slupphaug G, Krokan HE. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair 2004;3:1389-1407
16. Chen C-S, Lin JT, Goss KA, He Y, Halpert JR, Waxman DJ. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004;65:1278-1285
17. Chabner B, Longo DL, urednici. Cancer Chemotherapy and Biotherapy: Principles and Practice. 4. izd. Philadelphia (PA): Lippincot Williams and Wilkins; 2006.
18. Skeel RT, urednik. Handbook of Cancer Chemotherapy. 7. izd. Philadelphia: Lippincot Williams and Wilkins; 2007.
19. Paci A, Rieutord A, Brion F, Prognon P. Separation methods for alkylating antineoplastic compounds. J Chrom B 2001;764:255-287
20. British Columbia Cancer Agency (BCCA). BC Cancer Agency Cancer Drug Manualc Gemcitabine [pristup 20. siječnja 2010.]. Dostupno na http://www.bccancer. bc.ca/NR/rdonlyres/61DCBA09-705A-485C-9058- 05B892064E80/19547/Gemcitabinemonograph-2Nov06. pdf.
21. American Cancer Society, Lenhard RE, Osteen RT, Gansler TS, urednici. Clinical Oncology. 2. izd. Malden (MA): Blackwell Science Inc.; 2001.
22. Schellens JHM, McLeod HL, Newell DR, urednici. Cancer Clinical Pharmacology. New York (NY): Oxford University Press Inc., 2005.
23. Giaccone G, Schilsky R, Sondel P, urednici. Cancer Chemotherapy and Biological Response Modifiers: Annual 19. Amsterdam: Elsevier Science B.V.; 2001.
24. Vig BK. Genetic toxicology of mitomycin C, actinomycins, daunomycin and adriamycin. Mutat Res 1977;48:189-238.
25. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741
26. Vig BK, Lewis R. Genetic toxicology of bleomycin. Mutat Res 1978;55:121-145
27. Povirk LF, Austin MJF. Genotoxicity of bleomycin. Mutat Res 1991;257:127-143
28. Erexson GL, Bryant MF, Kwanyuen P, Kligerman AD. Bleomycin sulfate-induced micronuclei in human, rat, and mouse peripheral blood lymphocytes. Environ Mol Mutagen 1995;25:31-36
29. Gonzalez-Cid M, Mudry M, Larripa I. Chromosome damage induced by carboplatin (CBDCA). Toxicol Lett 1995;76:97-103.
30. British Columbia Cancer Agency (BCCA). BC Cancer Agency Cancer Drug Manualc Oxaliplatin [pristup 20. siječnja 2010.]. Dostupno na http://www.bccancer.bc.ca/NR/rdonlyres/ D0132051-8601-4B5E-89A0-5BB3B4739C83/ 31059/ Oxaliplatinmonograph-1Nov08-formatted.pdf.
31. Barton-Burke M, Wilkes GM, Ingwersen K, urednici. Cancer Chemotherapy: A Nursing Process Approach. 3. izd. Sudbury (MA): Jones and Bartlett Publishers, Inc.; 2001.
32. British Columbia Cancer Agency (BCCA). BC Cancer Agency Cancer Drug Manualc Procarbazine [pristup 20. siječnja 2010.]. Dostupno na http://www.bccancer. bc.ca/NR/rdonlyres/7B97C0C8-FFF9-4317-8397- 81E6268746A9/29592/Procarbazinemonograph-1July08. pdf.
33. British Columbia Cancer Agency (BCCA). BC Cancer Agency Cancer Drug Manualc Amsacrine [pristup 20. siječnja 2010.]. Dostupno na http://www.bccancer. bc.ca/NR/rdonlyres/DC04BEFB-BF13-4A48-91A8- 976A9650C6B8/30156/Amsacrinemonograph-1Sept08. pdf
34. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19(Suppl 9):1-10.
35. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19(Suppl 9):11-19
36. British Columbia Cancer Agency (BCCA). BC Cancer Agency Cancer Drug Manualc Estramustine [pristup 20. siječnja 2010.]. Dostupno na http://www.bccancer. bc.ca/NR/rdonlyres/93C68101-0CC1-43AA-BD89- DEB4E83F62FE/34099/Estramustinemonograph-1May09. pdf.
37. Migliore L, Cocchi R, Scarpato R, Sbrana I. Induction of aneuploidy by the antineoplastic drug estramustine in human lymphocytes. Mutat Res 1998;412:33-40.
38. Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 2006;56:354-365
39. Occupational Safety and Health Administration (OSHA). Office of Occupational Medicine Work Practice Guidelines for Personnel Dealing with Cytotoxic (Antineoplastic) Drugs. Occupational Safety and Health Administration Instruction publication. Washington (DC): US Dept of Labor; 1986.
40. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm 2006;63:1172-1193
41. QuapoS 4: Quality Standard for the Oncology Pharmacy Service With Commentary. 4. izd. Oldenburg: Onkopress; 2009.
42. Turci R, Sottani C, Spagnoli G, Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agent: a review of analytical methods. J Chrom B 2003;789:169-209.
43. World Health Organization (WHO). Biomarkers In Risk Assessment: Validity And Validation. Environmental Health Criteria 222, 2001 [pristup 20. siječnja 2010.]. Dostupno na http://www.inchem.org/documents/ehc/ehc/ ehc222.htm.
44. Norppa H, Sorsa M, Vainio H, Grohn P, Heinonen E, Holsti L, Nordman E. Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 1980;6:299-301.
45. Waksvik H, Klepp O, Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 1981;65:607-610
46. Kolmodin-Hedman B, Hartvig P, Sorsa M, Falck K. Occupational handling of cytostatic drugs. Arch Toxicol 1983;54:25-33.
47. Stiller A, Obe G, Boll I, Pribilla W. No elevation of the frequencies of chromosomal alterations as a consequence of handling cytostatic drugs: Analyses with peripheral blood and urine of hospital personnel. Mutat Res 1983;121:253-259
48. Barale R, Sozzi G, Toniolo P, Borghi O, Reali D, Loprieno N, Della Porta G. Sister-chromatid exchanges in lymphocytes and mutagenicity in urine of nurses handling cytostatic drugs. Mutat Res 1985;157:235-240
49. Jordan DK, Patil SR, Jochimsen PR, Lachenbruch PA, Corder MP. Sister chromatid exchange analysis in nurses handling antineoplastic drugs. Cancer Invest 1986;4:101-107
50. Pohlova H, Černa M, Rossner P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat Res 1986;174:213-217
51. Stucker I, Hirsch A, Doloy T, Bastie-Sigeac I, Hemon D. Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health 1986;57:195-205.
52. Benhamou S, Pot-Deprun J, Sancho-Garnier H, Chouroulinkov I. Sister-chromatid exchanges and chromosomal aberrations in lymphocytes of nurses handling cytostatic agents. Int J Cancer 1988;41:350-353
53. Sorsa M, Pyy L, Salomaa S, Nyland L, Yager JW. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res 1988;204:465-479
54. Krepinsky A, Bryant DW, Davison L, Heddle J, McCalla DR, Douglas G, Michalko K. Comparison of three assays for genetic effects of antineoplastic drugs on cancer patients and their nurses. Environ Mol Mutagen 1990;15:83-92.
55. Oestreicher U, Stephan G, Glatzel M. Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat Res 1990;242:271-277
56. Sarto F, Trevisan A, Tomanin R, Canova A, Fiorentino M. Chromosomal aberrations, sister chromatid exchanges and urinary thioethers in nurses handling antineoplastic drugs. Am J Ind Med 1990;18:689-695
57. Guinee EP, Beuman GH, Hageman G, Welle IJ, Kleinjans JC. Evaluation of genotoxic risk of handling cytostatic drugs in clinical pharmacy practice. Pharm Weekblad 1991;13:78-82.
58. Milkovǐ-Kraus S, Horvat D. Chromosomal abnormalities among nurses occupationally exposed to antineoplastic drugs. Am J Ind Med 1991;19:771-774
59. Thiringer G, Granung G, Holmen A, Hogstedt B, Jarvhom B, Jonsson D, Persson L, Wahlstrom J, Westin J. Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health 1991;17:133-138
60. Šardaš S, Gok, S, Karakaya AE. Sister chromatid exchanges in lymphocytes of nurses handling antineoplastic drugs. Toxicol Lett 1991;55:311-315
61. Goloni-Bertollo EM, Tajara EH, Manzato AJ, Varella-Garcia M. Sister chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs. Int J Cancer 1992;50:341-344
62. McDiarmid MA, Kolodner K, Humphrey F, Putman D, Jacobson-Kram D. Baseline and phosphoramide mustardinduced sister-chromatid exchanges in pharmacists handling anti-cancer drugs. Mutat Res 1992;279:199-204.
63. Gorecka D, Gorski T. The influence of cigarette smoking on sister chromatid exchange frequencies in peripheral lymphocytes among nurses handling cytostatic drugs. Pol J Occup Med Environ Health 1993;6:143-148
64. Roth S, Norppa H, Jarventaus H, Kyyronen P, Ahonen M, Lehtomaki J, Sainio H, Sorsa M. Analysis of chromosomal aberrations, sister chromatid exchanges and micronuclei in peripheral lymphocytes of pharmacists before and after working with cytostatic drugs. Mutat Res 1994;325:157-162
65. Peschke M, Nagel S, Haamann F, Melzer S, Meier K. Cytogenetic monitoring of pharmaceutical staff working with cytostatic drug preparations: A 5-year follow-up. J Oncol Pharm Pract 1995;1:33-39
66. Thulin H, Sundberg E, Hansson K, Cole J, Hartley-Asp B. Occupational exposure to nor-nitrogen mustard: Chemical and biological monitoring. Toxicol Ind Health 1995;11:89-97.
67. Brumen V, Horvat D. Work environment influence on cytostatics-induced genotoxicity in oncologic nurses. Am J Ind Med 1996;30:67-71.
68. Ensslin AS, Huber R, Pethran A, Rommelt H, Schierl R, Kulka U, Fruhmann G. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetic studies. Int Arch Occup Environ Health 1997;70:205-208
69. Fučić A, Jazbec A, Mijić A, Šešo- Šimić D, Tomek R. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Mutat Res 1998;416:59-66.
70. Kevekordes S, Gebel TW, Hellwig M, Dames W, Dunkelberg H. Human effect monitoring in cases of occupational exposure to antineoplastic drugs: A method comparison. Occup Environ Med 1998;55:145-149
71. Mahrous HS, Ismail SR, Hashishe MM, Kohail HM. Sister chromatid exchanges and chromosome aberrations in lymphocytes of medical personnel handling cytostatic drugs. J Egypt Public Health Assoc 1998;73:297-323.
72. Kašuba V, Rozgaj R, Garaj-Vrhovac V. Analysis of sister chromatid exchange and micronuclei in peripheral blood lymphocytes of murses handling cytostatic drugs. J Appl Toxicol 1999;19:401-404
73. Lanza A, Robustelli della Cuna FS, Zibera C, Pedrazzoli P, Robustelli della Cuna G. Somatic mutations at the T-cell antigen receptor in antineoplastic drug-exposed populations: comparison with sister chromatid exchange frequency. Int Arch Environ Health 1999;72:315-322
74. Pilger A, Kohler I, Stettner H, Mader RM, Rizovski B, Terkola R, Diem E, Franz-Hainzl E, Konnaris C, Valic E, Rudiger HV. Long-term monitoring of sister chromatid exchanges and micronucleus formation in pharmacy personnel occupationally exposed to cytostatic drugs. Int Arch Occup Environ Health 2000;73:442-448
75. Jakab MG, Major J, Tompa A. Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs. J Tox Environ Health 2001;62:307-318
76. Tompa A, Jakab M, Biro A, Magyar B, Fodor Z, Klupp T, Major J. Chemical Safety and Health Conditions among Hungarian Hospital Nurses. Ann NY Acad Sci 2006;1076:635-648
77. Ikeda K, Yagi Y, Tkegami M, Lu Y, Morimoto K, Kurokawa N. Efforts to ensure safety of hospital pharmacy personnel occupationally exposed to antineoplastic drugs during a preparation task. Hosp Pharm 2007;42:209-218
78. Kopjar N, Kašuba V, Rozgaj R, Želježić D, Milić M, Ramić S, Pavlica V, Milković-Kraus S. The genotoxic risk in health care workers occupationally exposed to cytotoxic drugs - A comprehensive evaluation by the SCE assay. J Environ Sci Health A 2009;44:462-479
79. Kopjar N, Garaj-Vrhovac V, Kašuba V, Rozgaj R, Ramić S, Pavlica V, Želježić D. Assessment of genotoxic risks in Croatian health care workers occupationally exposed to cytotoxic drugs: A multi-biomarker approach. Int J Hyg Environ Health 2009;212:414-431
80. Nikula E, Kiviniitty K, Leisti J, Taskinen PJ. Chromosome aberrations in lymphocytes of nurses handling cytostatic agents. Scand J Work Environ Health 1984;10:71-74
81. Rossner P, Černa M, Pokorana D, Hajek V, Petr J. Effect of ascorbic acid prophylaxis on the frequency of chromosome aberrations, urine mutagenicity and nucleolus test in workers occupationally exposed to cytostatic drugs. Mutat Res 1988;208:149-153
82. Medkova J. Cytogenetic analysis of peripheral lymphocytes in occupationally exposed health personnel. Acta Univ Palack Olomuc Facult Med 1990;126:93-106.
83. Cooke J, Williams J, Morgan RJ, Cooke P, Calvert RT. Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm 1991;48:1199-1205
84. Milković-Kraus S, Kraus O, Kršnjavi H, Kubelka D. Environmental effects on chromosomes in oncology and radiology department personnel. Prev Med 1992;21:498-502.
85. Grummt T, Grummt H-J, Schott G. Chromosomal aberrations in peripheral lymphocytes of nurses and physicians handling antineoplastic drugs. Mutat Res 1993;302:19-24.
86. Anwar WA, Salama SI, Serafy MM, Hermida S, Hafez AS. Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis 1994;9:315-317
87. Sessink PJM, Cerna M, Rossner P, Pastorkova A, Bavarova H, Frankova K, Anzion RB, Bos RP. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 1994;309:193-199
88. Rubeš J, Kucharova S, Vozdova M, Musilova P, Zudova Z. Cytogenetic analysis of peripheral lymphocytes in medical personnel by means of FISH. Mutat Res 1998;412:293-298
89. Ansari-Lari M, Saadat M, Shahryari M, Farhud DD. Sister Chromatid Exchanges and Micronuclei in Lymphocyte of Nurses Handling Antineoplastic Drug. Iranian J Publ Health 2001;30:37-40.
90. Burgaz S, Karahalil B, Canhi Z, Terzioglu F, Ancel G, Anzion RB, Bos RP, Huttner E. Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Hum Exp Toxicol 2002;21:129-135
91. Xu SJ. Wang JX. Yang DP. [An investigation on the chromosomal damage in nurses occupationally exposed to antineoplastic drugs, in Chinese]. Chin J Prev Med 2003;37:119-120
92. Dominguez Odio A, Batista Duharte A, Carnesoltas D, Romero Garcia LI, Loriega Loaces E, Cuello Almarales D, Landrove Mora Y, Garcia Cabrera L. Efectos citogeneticos por exposicion ocupacional a citostaticos [Cytogenetic effects after occupational exposure to cytostatics, in Spanish]. Rev Med IMSS 2004;42:487-492
93. Cavallo D, Ursini CL, Perniconi B, Di Francesco A, Giglio M, Rubino FM, Marinaccio A, Iavicoli S. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res 2005;587:45-51.
94. Testa A, Giachelia M, Palma S, Appolloni M, Padua L, Tranfo G, Spagnoli M, Trindelli D, Cozzi R. Occupational exposure to antineoplastic agents induces a high level of chromosome damage. Lack of an effect of GST polymorphisms. Toxicol Appl Pharmacol 2007;223:46-55.
95. Mušak L, Polakova V, Halašova E, Osina O, Vodićkova L, Buchancova J, Hudeákova H, Vodićka P. Effect of occupational exposure to cytostatics and nucleotide excision repair polymorphism on chromosomal aberrations frequency. Interdisc Toxicol 2009;2:13-17
96. Yager JW, Sorsa M, Selvin S. Micronuclei in cytokinesisblocked lymphocytes as an index of occupational exposure to alkylating cytostatic drugs. IARC Sci Publ 1988;89:213-216
97. Machado-Santelli GM, Cerqueira EM, Oliveira CT, de Braganca Peira CAA. Biomonitoring of nurses handling antineoplastic drugs. Mutat Res 1994;332:203-208
98. Garaj-Vrhovac V, Kopjar N. Micronuclei in cytokinesisblocked lymphocytes as an index of occupational exposure to antineoplastic drugs. Radiol Oncol 1998;32:385-392
99. Burgaz S, Karahalil B, Bayrak P, Taşkin L, Yavuzaslan F, Bokesoy I, Anzion RBM, Bos RP, Platin N. Urinary cyclophosphamide excretion and micronuclei frequencies in periperal lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 1999;439:97-104.
100. Maluf SW, Erdtmann B. Evaluation of occupational genotoxic risk in a Brazilian hospital. Genetics Mol Biol 2000;23:485-488
101. Maluf SW, Erdtmann B. Follow-up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Mutat Res 2000;471:21-27
102. Hessel H, Radon K, Pethran A, Maisch B, Grobmair S, Sautter I, Fruhmann G. The genotoxic risk of hospital, pharmacy and medical personnel occupationally exposed to cytostatic drugs-evaluation by the micronucleus assay. Mutat Res 2001;497:101-109
103. Deng H, Zhang M, He J, Wu W, Jin L, Zheng W, Lou J, Wang B. Investigating genetic damage in workers occupationally exposed to methotrexate using three genetic end-points. Mutagenesis 2005;20:351-357
104. Deng H, Lou J, Zhang M, Wu W, Jin L, Chen S, Zheng W, Wang B, He J. Detecting the cytogenetic effects in workers occupationally exposed to vincristine with four genetic tests. Mutat Res 2006;599:152-159
105. Laffon B, Teixeira JP, Silva S, Loureiro J, Torres J, Pasaro E, Mendez J, Mayan O. Genotoxic effects in a population of nurses handling antineoplastic drugs, and relationship with genetic polymorphisms in DNA repair enzymes. Am J Ind Med 2006;48:128-136
106. Cavallo D, Ursini CL, Omodeo-Sale E, Iavicoli S. Micronucleus induction and FISH analysis in buccal cells and lymphocytes of nurses handling antineoplastic drugs. Mutat Res 2007;628:11-18
107. Rekhadevi PV, Sailaja N, Chandrasekhar M, Mahboob M, Rahman MF, Grover P. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis 2007;22:395-401.
108. Cornetta T, Padua L, Testa A, Ievoli E, Festa F, Tranfo G, Baccelliere L, Cozzi R. Molecular biomonitoring of a population of nurses handling antineoplastic drugs. Mutat Res 2008;638:75-82.
109. Rombaldi F, Cassini C, Salvador M, SaffiJ, Erdtmann B. Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week. Mutagenesis 2009;24:143-148
110. Undeger U, Basaran N, Kars A, Guc D. Assessment of DNA damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Mutat Res 1999;439:277-285
111. Kopjar N, Garaj-Vrhovac V. Application of the alkaline comet assay in human biomonitoring for genotoxicity: A study on Croatian medical personnel handling antineoplastic drugs. Mutagenesis 2001;16:71-78
112. Yang D, Xu S, Wang J. [The study of DNA damage of peripheral lymphocytes in the nurses occupationally exposed to anticancer drugs, in Chinese]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2002;20:197-199
113. Ursini CL, Cavallo D, Colombi A, Giglio M, Marinaccio A, Iavicoli S. Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs. Int Arch Occup Environ Health 2006;80:134-140
114. Yoshida J, Kosaka H, Tomioka K, Kumagai S. Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan. J Occup Health 2006;48:517-522
115. Sasaki M, Dakeishi M, Hoshi S, Ishii N, Murata K. Assessment of DNA damage in Japanese nurses handling antineoplastic drugs by the comet assay. J Occup Health 2008;50:7-12.
116. Izdes S, Sardas S, Kadioglu E, Kaymak C, Ozcagli E. Assessment of Genotoxic damage in nurses occupationally exposed to anaesthetic gases or antineoplastic drugs by the comet assay. J Occup Health 2009;51:283-286
117. Perry P, Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature (London) 1974;251:156-158
118. Latt S, Allen J, Bloom SE, Carrano A, Falke E, Kram D, Schneider E, Schreck R, Tice R, Whitfield B, Wollf S. Sister chromatid exchanges: A report of the Gene-Tox Program. Mutat Res 1981;87:17-62.
119. Carrano AV, Natarajan AT. Considerations for population monitoring using cytogenetic techniques. Mutat Res 1988;204:379-406.
120. Morimoto K. Induction of sister chromatid exchanges and cell division delays in human lymphocytes by microsomal activation of benzene. Cancer Res 1983;43:1330-1334
121. Albertini RJ, Anderson D, Douglas GR, Hagmar L, Hemminki K, Merlo F, Natarajan AT, Norppa H, Shuker DEG, Tice R, Waters MD, Aitio A. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res 2000;463:111-172
122. Carrano AV, Moore DH. The rationale and methodology for quantifying sister chromatid exchange in humans. U: Heddle JA, urednik. Mutagenicity: New Horizons in Genetic Toxicology. New York (NY): Academic Press; 1982. str. 267-304.
123. Bonassi S, Fontana V, Ceppi M, Barale R, Bigeri A. Analysis of correlated data in human biomonitoring studies. The case of high sister chromatid exchange frequency cells. Mutat Res 1999;438:13-21.
124. Ponzanelli I, Landi S, Bernacchi F, Barale R. The nature of high frequency sister chromatid exchange cells (HFCs). Mutagenesis 1997;12:329-333
125. Hirsch BA, Sentz KK, McGue M. Genetic and environmental influences on baseline SCE. Environ Mol Mutagen 1992;20:2-11.
126. Lazutka JR, Dedonyte V, Krapavickaite D. Sister-chromatid exchanges and their distribution in human lymphocytes in relation to age, sex and smoking. Mutat Res 1994;306:173-180
127. Bolognesi C, Abbondandolo A, Barale R, Casalone R, Dalpra L, De Ferrari M, Degrassi F, Forni A, Lamberti L, Lando C, Migliore L, Padovani P, Pasquini R, Puntoni R, Sbrana I, Stella M, Bonassi S. Age-ralated increase of baseline frequencies of sister chromatid exchanges, chromosome aberrations and micronuclei in human lymphocytes. Cancer Epidem Biom Prev 1997;6:249-256
128. Bender MA, Preston J, Leonard RC, Pyatt BE, Gooch PC, Shelby MD. Chromosomal aberration and sister chromatid exchange frequencies in peripheral lymphocytes of a large human population sample. Mutat Res 1988;204:421-433
129. Anderson D, Francis AJ, Godbert P, Jenkinson PC, Butterworth KR. Variability in chromosome aberrations, sister chromatid exchanges, and mitogen-induced blastogenesis in peripheral lymphocytes from control individuals. Environ Health Persp 1993;101(Suppl 3):83-88
130. Sharma T, Das BC. Higher incidence of spontaneous sister-chromatid exchanges (SCEs) and X-ray-induced chromosome aberrations in peripheral blood lymphocytes during pregnancy. Mutat Res 1986;174:27-33.
131. Vijayalaxmi, Evans HJ. In vivo and in vitro effects of cigarette smoke on chromosomal damage and sister chromatid exchange in human peripheral blood lymphocytes. Mutat Res 1982;92:321-332
132. Obe G, Vogt HJ, Madle S, Fahning A, Heller WD. Doubleblind study on the effect of cigarette smoking on the chromosomes of human peripheral blood lymphocytes in vivo. Mutat Res 1982;92:309-319
133. Tucker JD, Ashworth LK, Johnston GR, Allen NA, Carrano AV. Variation in human lymphocyte sister-chromatid exchange frequency: result of a long-term longitudinal study. Mutat Res 1988;204:435-444
134. Reidy JA, Annest JL, Chen ATL, Welty TK. Increased sister chromatid exchange associated with smoking and coffee consumption. Environ Mol Mutagen 1988;12:311-318
135. Bonassi S, Bolognesi C, Abbondandolo A, Barale R, Bigatti P, Camurri L, Dalpra L, De Ferrari M, Forni A, Lando C, Padovani P, Pasquini R, Stella M, Puntoni R. Influence of sex on cytogenetic end points - evidence from a large human sample and review of the literature. Cancer Epidemiol Biomarkers Prev 1995;4:671-679
136. Slapšyte G, Jankauskiene A, Mieraiskiene J, Lazutka JR. Cytogenetic analysis of peripheral blood lymphocytes of children treated with nitrofurantion for recurrent urinary tract infection. Mutagenesis 2002;17:31-35
137. Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R. Low sensitivity of the sister chromatid exchange assay to detect the genotoxic effects of radioiodine therapy. Mutagenesis 1999;14:221-226
138. Jacobson-Kram D. The effects of diagnostic ultrasound on sister chromatid exchange frequencies: a review of the recent literature. J Clin Ultrasound 1984;12:5-10.
139. Garaj-Vrhovac V, Kopjar N. Cytogenetic monitoring of cardiology unit hospital workers exposed to ultrasound. J Appl Toxicol 2000;20:259-264
140. Atalay F, Baltaci V, Alpas I, Savas I, Atikcan S, Balci S. Sister chromatid exchange rate from pleural fluid cells in patient with malignant mesothelioma. Mutat Res 2000;465:159-163
141. Cortes-Guttierez EI, Cerda-Flores RM, Leal-Garza CH. Sister chromatid exchanges in peripheral lymphocytes from women with carcinoma of the uterine cervix. Cancer Genet Cytogenet 2000;122:121-123
142. Cottliar A, Fundia A, Boerr L, Sambuelli A, Negreira S, Gil A, Gomez JC, Chopita N, Bernedo A, Slavutsky I. High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. Am J Gastroenterol 2000;95:2301-2307
143. Carbonell E, Demopoulos NA, Stefanou G, Psaraki K, Parry EM, Marcos R. Cytogenetic analysis in peripheral lymphocytes of cancer patients treated with cytostatic drugs: Results from an EC Collaborative Study. Anticancer Drugs 1996;7:514-519
144. Kopjar N, Milas I, Garaj-Vrhovac V, Gamulin M. Cytogenetic outcomes of adjuvant chemotherapy in non-target cells of breast cancer patients. Hum Exp Toxicol 2007;26:391-399
145. Norppa H, Bonassi S, Hansteen I-L, Hagmar L, Stromberg U, Rossner P, Boffeta P, Lindholm C, Gundy S, Lazutka J, Cebulska-Wasilewska A, Fabianoca E, Šram RJ, Knudsen LE, Barale R, Fučić A. Chromosomal aberrations and SCEs as biomarkers of cancer risk. Mutat Res 2006;600:37-45.
146. Natarajan AT, Boei JJ, Darroudi F, Van Diemen PCM, Dulout F, Hande MP, Ramalho AT Current cytogenetic methods for detecting exposure and effects of mutagens and carcinogens. Environ Health Persp 1996;104(Suppl 3):445-448
147. Bender MA, Awa AA, Brooks AL, Evans HJ, Groer PO, Littlefield LG, Pereira C, Preston J, Wachholz BW. Current status of cytogenetic procedures to detect and quantify previous exposure to radiation. Mutat Res 1988;196:103-159
148. International Atomic Energy Agency (IAEA). Cytogenetic Analysis for Radiation Dose Assessment. Technical Report Series no. Vienna: IAEA; 2001.
149. Kopjar N, Želježić D, Garaj-Vrhovac V. Evaluation of DNA damage in the white blood cells of healthy human volunteers using the alkaline comet assay and the chromosome aberration test. Acta Biochim Pol 2006;53:321-336
150. Hagmar L, Bonassi S, Stromberg U, Mikoczy Z, Lando C, Hansten I-L, Huici Montagud A, Knudsen L, Norppa H, Reuterwall C, Tinnerberg H, Brogger A, Forni A, Hogstedt B, Lambert B, Mitelman F, Nordenson I, Salomaa S, Skerfving S. Cancer predictive value of cytogenetic markers used in occupational health surrveilance programs: a report from an ongoing study by the European Study Group on Cytogenetic Biomarkers and Health. Mutat Res 1998;405:171-178
151. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, Zeiger E. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 2003;534:65-75.
152. Salama S, Serrana M, Au WW. Biomonitoring using accessible human cells for exposure and health risk assessment. Mutat Res 1999;436:99-112.
153. Holland N, Bolognesi C, Kirsch-Volders M, Bonassi S, Zeiger E, Knasmueller S, Fenech M. The micronucleus assay in human buccal cells as a tool for biomonitoring DNA damage: The HUMN project perspective on current status and knowledge gaps. Mutat Res 2008;659:93-108.
154. Norppa H, Luomahaara S, Heikanen H, Roth S, Sorsa M, Renzi L, Lindholm C. Micronucleus assay in lymphocytes as a tool to biomonitor human exposure to aneuploidogens and clastogens. Environ Health Persp 1993;101(Suppl 3):139-143
155. Kirsch Volders M, Elhajouji A, Cundari E, Vanhumelen P. The in vitro micronucleus test - a multiendpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat Res 1997;392:19-30.
156. Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985;147:29-36.
157. Norppa H, Falck GCM. What do human micronuclei contain? Mutagenesis 2003;18:221-233
158. Schreiber GA, Beisker W, Braselmann H, Bauchinger M, Bogl KW, Nusse M. Automated flow cytometric micronucleus assay for human lymphocytes. Int J Radiat Biol 1992;62:695-709.
159. Verschaeve L, Vanderkerken M, Kirsch-Volders M. Cbanding as a simple tool to discriminate micronuclei induced by clastogens and aneugens. Stain Technol 1988;63:351-354
160. Mateuca R, Lombaert N, Aka PV, Decodier I, Kirsch-Volders M. Chromosomal changes: induction, detection methods and applicability in human biomonitoring. Biochemie 2006;88:1515-1531
161. Fenech M. The cytokinesis-block micronucleus technique: A detailed description of the method and its application to genotoxicity studies in human population. Mutat Res 1993;285:35-44.
162. Fenech M, Neville S, Rinaldi J. Sex is an important variable affecting spontaneous micronucleus frequency in cytokinesisblocked lymphocytes. Mutat Res 1994;313:203-207
163. Tucker JD, Nath J, Hando JC. Activation status of the X chromosome in human micronucleated lymphocytes. Hum Genet 1996;97:471-475
164. Fenech M, Morley AA. Kinetochore detection in micronuclei: an alternative method for measuring chromosome loss. Mutagenesis 1989;4:98-104.
165. Norppa H, Luomahaara S, Heikanen H, Roth S, Sorsa M, Renzi L, Lindholm C. Micronucleus assay in lymphocytes as a tool to biomonitor human exposure to aneuploidogens and clastogens. Environ Health Persp 1993;101(Suppl 3):139-143
166. Martinez-Perez LM, Cerda-Flores RM, Gallegos-Cabriales EC, Davila-Rodriguez MI, Ibarra-Costilla E, Cortes- Gutierrez EI. Frequency of micronuclei in Mexicans with type 2 diabetes mellitus. Prague Med Rep 2007;108:248-255
167. Masjedi MR, Heidary A, Mohammadi F, Velayati AA, Dokouhaki P. Chromosomal aberrations and micronuclei in lymphocytes of patients before and after exposure to antituberculosis drugs. Mutagenesis 2000;15:489-494
168. Milošević-Dordević O, Grujićić D, Marinković D, Arsenijević S, Banković S. Effect of various doses of gestogens on micronuclei frequency in human peripheral blood lymphocytes of pregnant women. Hum Reprod 2003;18:433-436
169. Cochran ST, Khodadoust A, Norman A. Cytogenetic effects of contrast material in patients undergoing excretory urography. Radiology 1980;136:43-46
170. Norman A, Cochran S, Bass D, Roe D. Effects of age, sex and diagnostic X-rays on chromosome damage. Int J Radiat Biol 1984;46:317-321
171. Larramendy ML, Knuutila S. Increased frequency of micronuclei in B and T8 lymphocytes from smokers. Mutat Res 1991;259:189-195
172. Bonassi S, Neri M, Lando C, Ceppi M, Lin Y, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Fenech M, The HUMN collaborative group. Effect of smoking habit on the frequency of micronuclei in human lymphocytes: results from the Human MicroNucleus project. Mutat Res 2003;543:155-166
173. Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti P, Bolognesi C, Cebulska-Wasilewska A, Fabianova E, Fučić A, Hagmar L, Joksić G, Martelli A, Migliore L, Mirkova E, ScarfiMR, Zijno A, Norppa H, Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 2007;28:625-631
174. Rojas E, Lopez MC, Valverde M. Single cell electrophoresis assay: methodology and applications. J Chrom B 1999;722:225-254
175. Singh NP. Microgels for estimation of DNA strand breaks, DNA protein crosslinks and apoptosis. Mutat Res 2000;455:111-127
176. Plappert U, Raddatz K, Roth S, Fliedner TM. DNA damage detection in man after radiation exposure - the comet assay - its possible application for human monitoring. Stem Cells 1995:13:215-222
177. Singh NP, McCoy MT, Tice RR, Schneider LL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-191
178. Olive PL. Applications of the comet assay in radiobiology. Int J Radiat Biol 1999;75:395-405.
179. Collins A, Dušinska M, Gedik C, Štetina R. Oxidative damage to DNA: Do we have a reliable marker? Environ Health Persp 1996;104(Suppl 3):465-469
180. Olive PL, Banath JP, Durand RE. Heterogeneity in radiationinduced DNA damage and repair in tumor and normal cells using the "comet" assay. Radiat Res 1990;122:86-94.
181. Wojewodzka M, Grádzka I, Buraczewska I. Modified neutral comet assay for human lymphocytes. Nukleonika 2002;47:1-5.
182. Pfeiffer P, Goedecke W, Obe G. Mechanisms of DNA double strand break repair and their potential to induce chromosomal aberrations. Mutagenesis 2000;15:289-302.
183. Speit G, Schutz P, Bonzheim I, Trenz K, Hoffmann H. Sensitivity of the FPG protein towards alkylation damage in the comet assay. Toxicol Lett 2004;146:151-158
184. Smith CC, O'Donovan MR, Martin EA. hOGG1 recognizes oxidative damage using the comet assay with greater specificity than FPG or ENDOIII. Mutagenesis 2006;21:185-190
185. Miyamae Y, Zaizen K, Ohara K, Mine Y, Sasaki YF. Detection of DNA lesions induced by chemical mutagens by the single cell gel electrophoresis (comet) assay. Relationship between the onset of DNA damage and the characteristics of mutagens. Mutat Res 1998;415:229-235
186. Tice RR. The single cell gel / comet assay: a microgel electrophoretic technique for the detection of DNA damage and repair in individual cells. U: Phillips DH, Vennit S, urednici. Environmental Mutagenesis. Oxford: Bioscientific; 1995. str. 315-339
187. Kaminskas E, Li JC. Repair of DNA damage induced by oxygen radicals in human non-proliferating and proliferating lymphocytes. Mutat Res 1992;274:103-110
188. Šalagović J, Maes A, Van Gorp U, Verschaeve L, Kalina I. The cell cycle positions Influence DNA migration as measured with the alkaline comet assay in stimulated human lymphocytes. Folia Biol (Praha) 1997;43:79-82.
189. Villani P, Altavista PL, Castaldi L, Leter G, Cordelli E. Analysis of DNA oxidative damage related to cell proliferation. Mutat Res 2000;464:229-237
190. Fortini P, Raspaglio G, Falchi M, Dogliotti E. Analysis of DNA alkylation damage and repair in mammalian cells by the comet assay. Mutagenesis 1996;11:169-175
191. Betti C, Davini T, Giannessi L, Loprieno N, Barale R. Microgel electrophoresis assay (comet test) and SCE analysis in human lymphocytes from 100 normal subjects. Mutat Res 1994;307:323-333
192. Wojewodzka M, Kruszewski M, Iwanenko T, Collins AR, Szumiel I. Application of the comet assay for monitoring DNA damage in workers exposed to chronic low-dose irradiation. I. Strand breakage. Mutat Res 1998;416:21-35.
193. Mendoza-Nunez VM, Sanchez-Rodriguez MA, Retana- Ugalde R, Vargas-Guadarrama LA, Altamirano-Lozano MA. Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly. Mech Ageing Dev 2001;122:835-847
194. Bajpayee M, Dhawan A, Parmar D, Kumar Pendey A, Mathur N, Seth PK. Gender-related differences in basal DNA damage in lymphocytes of a healthy Indian population using the alkaline comet assay. Mutat Res 2002;520:83-91.
195. Frenzilli G, Betti C, Davini T, Desideri M, Fornai E, Giannessi L, Maggiorelli F, Paoletti P, Barale R. Evaluation of DNA damage in leukocytes of ex-smokers by single cell gel electrophoresis. Mutat Res 1997;375:117-123
196. Zhu CQ, Lam TH, Jiang CQ, Wei BX, Lou X, Liu WW, Lao XQ, Chen YH. Lymphocyte DNA damage in cigarette factory workers measured by the comet assay. Mutat Res 1999;444:1-6.
197. Singh NP, Danner DB, Tice RR, Pearson JD, Brant LJ, Morrell CH, Schneider EL. Basal DNA damage in individual human lymphocytes with age. Mutat Res 1991;256:1-6.
198. Piperakis SM, Visvardis EE, Sagnou M, Tassiou AM. Effects of smoking and aging on oxidative DNA damage of human lymphocytes. Carcinogenesis 1998;19:695-698
199. Kopjar N, Želježić D, Garaj-Vrhovac V. Evaluation of DNA damage in the white blood cells of healthy human volunteers using the alkaline comet assay and the chromosome aberration test. Acta Biochim Pol 2006;53:321-336
200. Hellman B, Friis L, Vaghef H, Edling C. Alkaline single cell gel electrophoresis and human biomonitoring for genotoxicity: a study on subjects with residential exposure to radon. Mutat Res 1999;442:121-132
201. Moller P, Wallin H, Holst E, Knudsen LE. Sunlight-induced DNA damage in human mononuclear cells. FASEB J 2002;16:45-53.
202. Verschaeve L, Koppen G, Gorp UV, Schoeters G, Jacobs G, Zwijzen C. Seasonal variations in spontaneous levels of DNA damage; implication in the risk assessment of environmental chemicals. J Appl Toxicol 2007;27:612-620
203. Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R. The alkaline single-cell gel electrophoresis (SCGE) assay applied to the analysis of radiation-induced DNA damage in thyroid cancer patients treated with 131I. Mutat Res 1998;413:111-119
204. Dantas FJ, de Mattos JC, Moraes MO, Boasquevisques E, Rodrigues MP, Lage CA, Cabral-Neto JB, Leitao AC, Bernardo-Filho M, Bezerra RJ, Carvalho JJ, Caldeira-de- Araujo A. DNA damage in peripheral blood nuclear cells assessed by comet assay from individuals submitted to scintigraphic examinations. Cell Mol Biol 2002;48:789-791
205. Biri A, Civelek E, Karahalil B, Sardaş S. Assessment of DNA damage in women using oral contraceptives. Mutat Res 2002;521:113-119
206. Milković D, Garaj-Vrhovac V, Ranogajec-Komor M, Miljanić S, Gajski G, Knežević Ž, Beck N. Primary DNA damage assessed with the comet assay and comparison to the absorbed dose of diagnostic X-rays in children. Int J Toxicol 2009;5:405-416
207. Mastaloudis A, Yu T-W, O'Donnel RP, Frei B, Dashwood RH, Traber MG. Endurance exercise results in DNA damage as detected by the comet assay. Free Radical Biol Med 2004;36:966-975
208. Moller P, Knudsen LE, Frentz G, Dybdahl M, Wallin H, Nexo BA. Seasonal variation of DNA damage and repair in patients with non-melanoma skin cancer and referents with and without psoriasis. Mutat Res 1998;407:25-34.
209. Mozaffarieh M, Schoetzau A, Sauter M, Grieshaber M, Orgul S, Golubnitschaja O, Flammer J. Comet assay analysis of single-stranded DNA breaks in circulating leukocytes of glaucoma patients. Mol Vis 2008;14:1584-1588
210. Bilgici B, Bedir A, Šenturk N, Alvur M, Aydin F, Turanli AY. Genotoxicity assessment using comet assay in Behcet's disease patients. Mutat Res 2005;578:170-174
211. Hininger I, Chollat-Namy A, Sauvagio S, Osman M, Faure H, Cadet J, Favier A, Rousell A-M. Assessment of DNA damage by comet assay on frozen total blood: method and evaluation in smokers and non-smokers. Mutat Res 2004;558:75-80.
212. Rapp A, Hausmann M, Greulich KO. The comet-FISH technique: a tool for detection of specific DNA damage and repair. Methods Mol Biol 2005;291:107-119